publication venue for
- Ustekinumab demonstrates rapid onset of efficacy in the treatment of moderate-to-severe psoriasis 2010
-
Age affects drug survival rates of interleukin (
IL )‐17 andIL ‐23 inhibitors in patients with plaque psoriasis: Results from a retrospective, multicentric, multi‐country, cohort study. 38:2175-2185. 2024 - Effectiveness and safety of risankizumab dose optimization in adult patients with plaque psoriasis: An international multicentre retrospective cohort study. 2024
- Considerations for defining and diagnosing generalized pustular psoriasis. 2024
- Risk factors for malignancy in adult‐onset dermatomyositis. 38:e122-e124. 2024
- Speed of clinical improvement in the real‐world setting from patient‐reported Psoriasis Symptoms and Signs Diary: Secondary outcomes from the Psoriasis Study of Health Outcomes through 12 weeks. 37:1825-1840. 2023
- Incidence and prognosis of COVID‐19 in patients with psoriasis on apremilast: a multicentre retrospective cohort study. 36:e94-e95. 2022
- Incidence and prognosis of COVID‐19 in psoriasis patients on biologic therapy: a multicentre retrospective cohort study. 35:e485-e487. 2021
- Position statement for a pragmatic approach to immunotherapeutics in patients with inflammatory skin diseases during the coronavirus disease 2019 pandemic and beyond. 35:797-806. 2021
- Psoriasis patients’ preference for an aerosol foam topical formulation. 32:e400-e401. 2018
- Effect of tofacitinib withdrawal and re‐treatment on patient‐reported outcomes: results from a Phase 3 study in patients with moderate to severe chronic plaque psoriasis. 31:323-332. 2017
- Etanercept for patients with psoriasis who did not respond or who lost their response to adalimumab or infliximab. 29:1576-1581. 2015
- Narrowband UVB therapy for vitiligo: does the repigmentation last? (vol 21, pg 891, 2007). 22:139-139. 2008
- Narrowband UVB therapy for vitiligo: does the repigmentation last?. 21:891-896. 2007